William Conkling - 02 Jun 2026 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Reporting relationship: Chief Commercial Officer
Issuer ticker: TARA
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 16:55:06 UTC
Prior SEC filing: 21 Jan 2026
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: William Conkling

Key filing fact

William Conkling filed Form 4 for Protara Therapeutics, Inc. (TARA) on 03 Jun 2026.

Key facts

This page summarizes William Conkling's Form 4 filing for Protara Therapeutics, Inc. (TARA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2026, 16:55.

Change

Previous filing in this sequence was filed on 21 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001852018 Primary reporting owner

CONKLING WILLIAM

Relationship: Chief Commercial Officer
Address: C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH 3RD FLOOR, NEW YORK
Signature: William Conkling
Signature date: 03 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARA transaction

Common Stock

Tax liability

Transaction value
Shares: -6,008
Change %: -7.9%
Price: $4.34^*
Shares after: 69,992
Date: 02 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on June 2, 2025.